Online inquiry

IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1957MR)

This product GTTS-WQ1957MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SLITRK6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_032229.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84189
UniProt ID Q9H5Y7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1957MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8266MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ4334MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ15604MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ10876MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ3002MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ10536MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ13496MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ11977MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW